See Shionogi-Sponsored Publications

Publications

Here, you can review available Shionogi-sponsored publications. If you would like an electronic copy of one of the journal publications on this page, please contact
Shionogi Medical Information for further assistance.

Information about investigational compounds or investigational uses of products does not imply FDA approval of these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the investigational compounds or investigational uses of products will receive FDA approval. Shionogi does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.

  • All
  • Cefiderocol
  • Ensitrelvir
  • Zatolmilast
  • All
  • In vitro
  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4
  • Real-world evidence
  • Surveillance
  • Review
  • Pharmacokinetics/Pharmaco-dynamics
  • Compatibility
  • All
  • Gram-negative infection
  • COVID-19
  • Fragile X syndrome
 
Cefiderocol
Review
Gram-negative infection

All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies

Published:
2022
Authors:
Lodise TP, Bassetti M, Ferrer R, et al.
View Publication
 
Cefiderocol
Phase 3
Gram-negative infection

Cefiderocol for the treatment of infections due to metallo-beta-lactamase-producing pathogens in the CREDIBLE-CR and APEKS-NP phase 3 randomized studies

Published:
2022
Authors:
Timsit JF, Paul M, Shields RK, et al.
View Publication
 
Ensitrelvir
In vitro
COVID-19

Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor cinical candidate for treating COVID-19

Published:
2022
Authors:
Unoh Y, Uehara S, Nakahara K, et al.
View Publication
 
Cefiderocol
Phase 3
Gram-negative infection

Evidence for efficacy of cefiderocol against OXA-48-containing Isolates from the APEKS-NP and CREDIBLE-CR trials

Published:
2022
Authors:
Longshaw C, Roger E, Santerre Henriksen A, et al.
View Publication
 
Cefiderocol
Surveillance
Gram-negative infection

In vitro activity of cefiderocol against U.S. and European Gram-negative clinical isolates collected in 2020 as part of the SENTRY antimicrobial surveillance program

Published:
2022
Authors:
Shortridge D, Streit JM, Mendes R, et al.
View Publication